

Table 14.10
De Novo Posttransplant Solid Malignancy, 2000 to 2009
Heart Recipients

	Year of Transplant									
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Total # of Post-Tx Malignancies	583	504	413	331	276	293	222	141	82	28
Malignancies by Type										
Squamous/Basal Cell Carcinoma	318	312	240	200	147	177	144	77	56	16
Melanoma	19	19	10	16	11	11	10	5	2	1
Kaposi Sarcoma	-	1	-	-	-	-	3	3	2	-
Central Nervous System	5	-	-	-	-	1	3	-	-	-
Genito-Urinary (1)	82	58	50	47	49	40	32	17	5	2
Gastro-Intestinal (2)	34	19	23	19	9	8	10	9	3	2
Primary Hepatic Tumor	3	3	-	1	-	1	-	1	-	-
Metastatic Hepatic Tumor	5	3	7	6	3	1	-	-	1	-
Larynx/Bronchi/Lung	55	51	45	23	31	27	8	12	4	3
Breast/Thyroid	10	17	7	9	7	9	6	9	1	-
Leukemia	2	-	6	-	5	2	-	-	-	1
Sarcoma (3)	4	1	4	-	1	-	-	-	-	-
Other	41	18	21	8	12	15	4	7	8	3
Unknown	5	2	-	2	1	1	2	1	-	-
Malignancies by Type (%)										
Squamous/Basal Cell Carcinoma	54.5%	61.9%	58.1%	60.4%	53.3%	60.4%	64.9%	54.6%	68.3%	57.1%
Melanoma	3.3%	3.8%	2.4%	4.8%	4.0%	3.8%	4.5%	3.5%	2.4%	3.6%
Kaposi Sarcoma	-	0.2%	-	-	-	-	1.4%	2.1%	2.4%	-
Central Nervous System	0.9%	-	-	-	-	0.3%	1.4%	-	-	-
Genito-Urinary (1)	14.1%	11.5%	12.1%	14.2%	17.8%	13.7%	14.4%	12.1%	6.1%	7.1%
Gastro-Intestinal (2)	5.8%	3.8%	5.6%	5.7%	3.3%	2.7%	4.5%	6.4%	3.7%	7.1%
Primary Hepatic Tumor	0.5%	0.6%	-	0.3%	-	0.3%	-	0.7%	-	-
Metastatic Hepatic Tumor	0.9%	0.6%	1.7%	1.8%	1.1%	0.3%	-	-	1.2%	-
Larynx/Bronchi/Lung	9.4%	10.1%	10.9%	6.9%	11.2%	9.2%	3.6%	8.5%	4.9%	10.7%
Breast/Thyroid	1.7%	3.4%	1.7%	2.7%	2.5%	3.1%	2.7%	6.4%	1.2%	-
Leukemia	0.3%	-	1.5%	-	1.8%	0.7%	-	-	-	3.6%
Sarcoma (3)	0.7%	0.2%	1.0%	-	0.4%	-	-	-	-	-
Other	7.0%	3.6%	5.1%	2.4%	4.3%	5.1%	1.8%	5.0%	9.8%	10.7%
Unknown	0.9%	0.4%	-	0.6%	0.4%	0.3%	0.9%	0.7%	-	-
Total # of Patients	330	294	245	203	181	180	150	110	66	24

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

(-) = None in category.

(1) Genito-Urinary: kidney, bladder, uterine cervix, uterine body, ovarian, vulva, testicular, prostate.

(2) Gastro-Intestinal: tongue, throat, esophagus, stomach, small intestine, colo-rectal, liver and biliary tract, pancreas.

(3) Sarcoma: fibrosarcoma, osteosarcoma, etc.

Recipient malignancy statistics are based on voluntary reporting to the OPTN.